Arovella Therapeutics Limited

ASX:ALA 주식 보고서

시가총액: AU$194.9m

Arovella Therapeutics 관리

관리 기준 확인 1/4

Arovella Therapeutics' CEO is Michael Baker, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is A$558.31K, comprised of 60.9% salary and 39.1% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth A$1.21M. The average tenure of the management team and the board of directors is 1.5 years and 2.7 years respectively.

주요 정보

Michael Baker

최고 경영자

AU$558.3k

총 보상

CEO 급여 비율60.9%
CEO 임기4.8yrs
CEO 소유권0.6%
경영진 평균 재임 기간1.5yrs
이사회 평균 재임 기간2.7yrs

최근 관리 업데이트

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

CEO 보상 분석

Michael Baker 의 보수는 Arovella Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024AU$558kAU$340k

-AU$9m

Mar 31 2024n/an/a

-AU$9m

Dec 31 2023n/an/a

-AU$10m

Sep 30 2023n/an/a

-AU$10m

Jun 30 2023AU$528kAU$325k

-AU$10m

Mar 31 2023n/an/a

-AU$9m

Dec 31 2022n/an/a

-AU$9m

Sep 30 2022n/an/a

-AU$9m

Jun 30 2022AU$604kAU$303k

-AU$9m

Mar 31 2022n/an/a

-AU$8m

Dec 31 2021n/an/a

-AU$7m

Sep 30 2021n/an/a

-AU$6m

Jun 30 2021AU$403kAU$275k

-AU$5m

Mar 31 2021n/an/a

-AU$5m

Dec 31 2020n/an/a

AU$2m

Sep 30 2020n/an/a

-AU$1m

Jun 30 2020AU$385kAU$124k

-AU$4m

보상 대 시장: Michael's total compensation ($USD368.74K) is about average for companies of similar size in the Australian market ($USD299.27K).

보상과 수익: Michael's compensation has increased whilst the company is unprofitable.


CEO

Michael Baker

4.8yrs

테뉴어

AU$558,311

보상

Dr. Michael Baker serves as Chief Executive Officer of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd). since January 2, 2020 and served as its Executive Chairman until July 1, 2...


리더십 팀

이름위치테뉴어보상소유권
Michael Baker
CEO, MD & Director4.8yrsAU$558.31k0.62%
A$ 1.2m
Nicole van der Weerden
Chief Operating Officer1.8yrsAU$423.15k0.078%
A$ 152.1k
Timothy Luscombe
Company Secretary & CFOless than a year데이터 없음데이터 없음
Michelle Long
Administration Manager1.3yrs데이터 없음데이터 없음

1.5yrs

평균 재임 기간

경험이 풍부한 관리: ALA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


이사회 구성원

이름위치테뉴어보상소유권
Michael Baker
CEO, MD & Director4.8yrsAU$558.31k0.62%
A$ 1.2m
Gary Phillips
Independent Non-Executive Director2.3yrsAU$84.38k0.075%
A$ 145.9k
Elizabeth Stoner
Independent Non-Executive Director3yrsAU$116.13k0.072%
A$ 141.2k
Thomas Duthy
Non-Executive Chair1.7yrsAU$332.53k0.45%
A$ 878.3k
Sattva Neelapu
Member of Clinical Advisory Boardless than a year데이터 없음데이터 없음
Gianpietro Dotti
Member of Scientific Advisory Boardless than a year데이터 없음데이터 없음
Debora Barton
Member of Clinical Advisory Board & Independent Non-Executive Director3.3yrsAU$115.94k0.025%
A$ 48.7k
Reuben Benjamin
Member of Scientific Advisory Board3.3yrs데이터 없음데이터 없음
John Maher
Member of Scientific Advisory Board3.2yrs데이터 없음데이터 없음
Anastasios Karadimitris
Chairman of Scientific Advisory Boardno data데이터 없음데이터 없음
Salvatore Fiorenza
Chair of Clinical Advisory Boardless than a year데이터 없음데이터 없음

2.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: ALA's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.